Tumor necrosis factor: How to make a killer molecule tumor-specific?

Rudolf Lucas, Matthias Kresse, Markus Latta, Albrecht Wendel

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

The interest in TNF, discovered at the interface between inflammation and cancer, as an anti-cancer agent, has phased out in recent years. Indeed, despite its profound cytostatic and cytotoxic effects in primary tumors, the cytokine's systemic toxicity in general and its hepatotoxic and pro-metastatic nature in particular, prevent its routine use in cancer patients. An elegant approach to circumvent these problems consists in the local application of TNF in an isolated limb or organ setting, preferentially in the presence of cytostatic and alkylating agents, such as melphalan. However, this treatment, when locally applied during the perfusion of liver tumors, results in hepatotoxicity in a significant number of the patients, by means of a still unknown mechanism. The hemorrhagic necrosis of the tumors induced by TNF seems to be predominantly mediated by an induction of apoptosis as well as by an anti-angiogenic effect in the endothelial cells of the microvasculature supplying the tumor. These cells therefore represent a prime target for the action of anti-cancer drugs. In this review, we discuss preclinical studies which elucidated the mechanism of melphalan- and TNF-associated hepatotoxicity and, as a consequence, provided insights for preventing the adverse reactions of the drug. Moreover, we review recent findings aimed at improving the TNF molecule by means of specific mutations, or searching for alternative factors lacking the systemic toxicity of TNF.

Original languageEnglish (US)
Pages (from-to)381-392
Number of pages12
JournalCurrent cancer drug targets
Volume5
Issue number6
DOIs
StatePublished - Sep 1 2005

Fingerprint

Tumor Necrosis Factor-alpha
Neoplasms
Melphalan
Cytostatic Agents
Alkylating Agents
Microvessels
Drug-Related Side Effects and Adverse Reactions
Necrosis
Extremities
Endothelial Cells
Perfusion
Apoptosis
Cytokines
Inflammation
Mutation
Liver
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Tumor necrosis factor : How to make a killer molecule tumor-specific? / Lucas, Rudolf; Kresse, Matthias; Latta, Markus; Wendel, Albrecht.

In: Current cancer drug targets, Vol. 5, No. 6, 01.09.2005, p. 381-392.

Research output: Contribution to journalReview article

Lucas, Rudolf ; Kresse, Matthias ; Latta, Markus ; Wendel, Albrecht. / Tumor necrosis factor : How to make a killer molecule tumor-specific?. In: Current cancer drug targets. 2005 ; Vol. 5, No. 6. pp. 381-392.
@article{3750402b204d42e18f8eb05ec4a463f1,
title = "Tumor necrosis factor: How to make a killer molecule tumor-specific?",
abstract = "The interest in TNF, discovered at the interface between inflammation and cancer, as an anti-cancer agent, has phased out in recent years. Indeed, despite its profound cytostatic and cytotoxic effects in primary tumors, the cytokine's systemic toxicity in general and its hepatotoxic and pro-metastatic nature in particular, prevent its routine use in cancer patients. An elegant approach to circumvent these problems consists in the local application of TNF in an isolated limb or organ setting, preferentially in the presence of cytostatic and alkylating agents, such as melphalan. However, this treatment, when locally applied during the perfusion of liver tumors, results in hepatotoxicity in a significant number of the patients, by means of a still unknown mechanism. The hemorrhagic necrosis of the tumors induced by TNF seems to be predominantly mediated by an induction of apoptosis as well as by an anti-angiogenic effect in the endothelial cells of the microvasculature supplying the tumor. These cells therefore represent a prime target for the action of anti-cancer drugs. In this review, we discuss preclinical studies which elucidated the mechanism of melphalan- and TNF-associated hepatotoxicity and, as a consequence, provided insights for preventing the adverse reactions of the drug. Moreover, we review recent findings aimed at improving the TNF molecule by means of specific mutations, or searching for alternative factors lacking the systemic toxicity of TNF.",
author = "Rudolf Lucas and Matthias Kresse and Markus Latta and Albrecht Wendel",
year = "2005",
month = "9",
day = "1",
doi = "10.2174/1568009054863627",
language = "English (US)",
volume = "5",
pages = "381--392",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Tumor necrosis factor

T2 - How to make a killer molecule tumor-specific?

AU - Lucas, Rudolf

AU - Kresse, Matthias

AU - Latta, Markus

AU - Wendel, Albrecht

PY - 2005/9/1

Y1 - 2005/9/1

N2 - The interest in TNF, discovered at the interface between inflammation and cancer, as an anti-cancer agent, has phased out in recent years. Indeed, despite its profound cytostatic and cytotoxic effects in primary tumors, the cytokine's systemic toxicity in general and its hepatotoxic and pro-metastatic nature in particular, prevent its routine use in cancer patients. An elegant approach to circumvent these problems consists in the local application of TNF in an isolated limb or organ setting, preferentially in the presence of cytostatic and alkylating agents, such as melphalan. However, this treatment, when locally applied during the perfusion of liver tumors, results in hepatotoxicity in a significant number of the patients, by means of a still unknown mechanism. The hemorrhagic necrosis of the tumors induced by TNF seems to be predominantly mediated by an induction of apoptosis as well as by an anti-angiogenic effect in the endothelial cells of the microvasculature supplying the tumor. These cells therefore represent a prime target for the action of anti-cancer drugs. In this review, we discuss preclinical studies which elucidated the mechanism of melphalan- and TNF-associated hepatotoxicity and, as a consequence, provided insights for preventing the adverse reactions of the drug. Moreover, we review recent findings aimed at improving the TNF molecule by means of specific mutations, or searching for alternative factors lacking the systemic toxicity of TNF.

AB - The interest in TNF, discovered at the interface between inflammation and cancer, as an anti-cancer agent, has phased out in recent years. Indeed, despite its profound cytostatic and cytotoxic effects in primary tumors, the cytokine's systemic toxicity in general and its hepatotoxic and pro-metastatic nature in particular, prevent its routine use in cancer patients. An elegant approach to circumvent these problems consists in the local application of TNF in an isolated limb or organ setting, preferentially in the presence of cytostatic and alkylating agents, such as melphalan. However, this treatment, when locally applied during the perfusion of liver tumors, results in hepatotoxicity in a significant number of the patients, by means of a still unknown mechanism. The hemorrhagic necrosis of the tumors induced by TNF seems to be predominantly mediated by an induction of apoptosis as well as by an anti-angiogenic effect in the endothelial cells of the microvasculature supplying the tumor. These cells therefore represent a prime target for the action of anti-cancer drugs. In this review, we discuss preclinical studies which elucidated the mechanism of melphalan- and TNF-associated hepatotoxicity and, as a consequence, provided insights for preventing the adverse reactions of the drug. Moreover, we review recent findings aimed at improving the TNF molecule by means of specific mutations, or searching for alternative factors lacking the systemic toxicity of TNF.

UR - http://www.scopus.com/inward/record.url?scp=23844470601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844470601&partnerID=8YFLogxK

U2 - 10.2174/1568009054863627

DO - 10.2174/1568009054863627

M3 - Review article

C2 - 16178815

AN - SCOPUS:23844470601

VL - 5

SP - 381

EP - 392

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 6

ER -